engleski

Immunosuppressive and anti-dyslipidemic treatment after kidney and kidney-pancreas transplantation

Hyperlipidemia is a frequent finding among renal transplant recipients. Treatment of dyslipidemias should be part of routine post-renal transplant care. Our results show a high incidence of hyperlipidemia in patients with KT and SPKT, which is in line with results from other published studies. The largest number of transplanted patients was on corticosteroid therapy. The most frequent used anti-dyslipidemic drug was fluvastatin according to the largest experience (ALERT study).

dyslipidemia; kidney transplantation; kidney-pancreas transplantation

nije evidentirano